Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Azacitidine,RIGOSERTIB SODIUM (ON 01910.Na)
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of rigosertib combined with Vidaza® (azacitidine) that can be given to patients with MDS, AML, or CMML. The goal of Phase II is to learn if rigosertib combined with azacitidine can help control MDS, AML, or CMML. The safety of this drug combination will also be studied.
Disease Group: Leukemia
Treatment Agent: Azacitidine,RIGOSERTIB SODIUM (ON 01910.Na)
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Onconova Therapeutics Inc.
IRB Review and Approval Date: 05/09/2017
Recruitment Status: Open
Projected Accrual: Up to 80
Information and next steps
Phase I/Phase II
For general questions about clinical trials: